Advertisement
ABBV vs BMY
Which Stock Would AI Choose? AbbVie (ABBV) vs. Bristol Myers Squibb (BMY) Stock Comparison
Key Takeaways
- ABBV has delivered stronger relative performance in recent quarters, supported by the rapid growth of its Skyrizi and Rinvoq immunology franchises as they offset Humira erosion.
- BMY trades at a lower forward price-to-earnings (P/E) multiple than large-cap pharma peers, reflecting a mix of pipeline optimism and patent-cliff concerns.
- Both companies are managing "patent cliffs" — the loss of exclusivity on blockbuster drugs — but ABBV appears further along in replacing lost revenue than BMY.
- BMY's newer growth portfolio, including Opdivo, Reblozyl, Camzyos, and Breyanzi, is growing quickly but has not yet fully offset steep declines in its legacy products.
- Each stock pays a dividend and has recently raised its payout, though ABBV's dividend growth has been more substantial.
- For more detail on these names, explore ABBV Major News and ABBV Today's Price Move, as well as BMY Major News and BMY Today's Price Move.
- Interested in data-driven market signals? Explore Trending AI Robots to see which automated strategies are currently favored.
Introduction
AbbVie and Bristol Myers Squibb are two of the largest pharmaceutical companies in the United States, yet they present investors with meaningfully different risk-and-reward profiles. Both are navigating the transition away from aging blockbusters toward newer medicines, making this a useful stock comparison for those weighing growth momentum against valuation. Income-oriented investors may find the dividend profiles relevant, while growth-focused traders may be more interested in the pace of new-drug launches and pipeline catalysts. This article examines recent business developments, relative performance, and market positioning to help readers understand how these two healthcare leaders stack up in the current environment.
ABBV Overview and Recent Performance
AbbVie (ABBV) is a diversified biopharmaceutical company with strengths in immunology, oncology, neuroscience, and aesthetics. Its recent market activity has reflected confidence in its post-Humira strategy. After losing U.S. exclusivity for Humira — its former top-selling arthritis drug — AbbVie has leaned heavily on Skyrizi and Rinvoq, two newer immunology medicines that have grown rapidly and now anchor the portfolio.
In recent quarters, AbbVie reported double-digit revenue growth, driven by strong demand for these drugs alongside contributions from neuroscience products such as Vraylar and the newer Parkinson's therapy Vyalev. Management has raised its annual earnings guidance and increased its quarterly dividend by 5.5%, signaling conviction in sustained cash generation. The company has also been an active acquirer, pursuing deals and licensing agreements to broaden its pipeline. Areas of softness include declining Imbruvica sales and weaker demand for aesthetics products such as Botox, though these have not derailed the broader growth narrative.
BMY Overview and Recent Performance
Bristol Myers Squibb (BMY) is a global biopharmaceutical company with a leading position in oncology, along with franchises in hematology, cardiovascular, and immunology. Its recent performance has been more mixed. The company's "Growth Portfolio" — headlined by immuno-oncology drug Opdivo, plus Reblozyl, Camzyos, and CAR T-cell therapy Breyanzi — has posted strong sales increases, and the newly approved schizophrenia drug Cobenfy offers a new growth avenue.
However, these gains have been partially offset by generic competition eroding legacy products such as Revlimid, Pomalyst, Sprycel, and Abraxane. Eliquis, the company's top-selling blood thinner co-marketed with Pfizer, remains a key contributor but faces a potential patent cliff later this decade. In recent months, Bristol Myers has received several analyst upgrades citing pipeline momentum, and it announced a modest dividend increase. Still, the stock's valuation remains discounted relative to peers, reflecting ongoing uncertainty about how quickly new launches can replace declining legacy revenue.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies designed to adapt to shifting market conditions. Tickeron maintains hundreds of AI trading bots that collectively monitor thousands of different tickers, but only the best-performing and most suitable strategies for the current environment earn a place in this section. These bots vary widely in trading style, strategy, timeframe, risk profile, and the specific tickers they trade, giving investors a range of options to match their own objectives. Because the selection is refreshed to reflect prevailing market dynamics, the page serves as a useful starting point for those seeking data-driven, systematic approaches to the market. Explore Trending AI Robots to review the current lineup.
Head-to-Head Comparison
The clearest contrast between these two stocks is the stage of their respective patent-cliff transitions. AbbVie has largely absorbed the Humira decline and returned to solid top-line growth, while Bristol Myers Squibb is still working to offset meaningful erosion in its legacy franchise. This difference is reflected in relative performance: AbbVie's shares have shown stronger momentum, while BMY trades at a lower forward earnings multiple that prices in execution risk.
In terms of business model, both companies are diversified drugmakers, but their growth drivers differ. AbbVie's momentum is concentrated in immunology and neuroscience, whereas BMY's is anchored in oncology and hematology, with an emerging psychiatry opportunity in Cobenfy. Risk factors also diverge: AbbVie faces pricing-policy scrutiny and softer aesthetics demand, while BMY confronts steeper generic headwinds and near-term patent exposure. Sentiment has favored AbbVie recently, while BMY has attracted a mix of upgrades and cautious "hold" ratings as investors weigh pipeline potential against near-term revenue pressure.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalyst positioning, Tickeron's AI would likely favor AbbVie over Bristol Myers Squibb in the current environment. AbbVie's stronger relative performance, clearer post-patent-cliff earnings trajectory, and more robust dividend growth suggest steadier momentum. Bristol Myers Squibb offers a compelling valuation and genuine pipeline catalysts, but its transition appears earlier-stage and carries more execution uncertainty. Accordingly, an AI-driven assessment would lean toward AbbVie on a risk-adjusted basis, while acknowledging that BMY's discounted valuation could appeal to investors with a higher tolerance for uncertainty and a longer time horizon.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and BMY is a Buy.
ABBV's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ABBV turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 52 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 213 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-87.802) is very low in comparison to the industry average of (-1.376). ABBV has a moderately high P/E Ratio (83.302) as compared to the industry average of (21.842). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.039) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
BMY's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BMY turned positive on October 16, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in 32 of 49 cases over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Indicator exited the oversold zone, 19 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 61%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BMY as a result. In 46 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
BMY moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 174 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 68 cases where BMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BMY broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BMY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.718) is normal, around the industry mean (-1.376). P/E Ratio (13.702) is within average values for comparable stocks, (21.842). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.040) settles around the average of (0.039) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
ABBV | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 2 | 69 | |
SMR RATING 1..100 | 1 | 22 | |
PRICE GROWTH RATING 1..100 | 9 | 45 | |
P/E GROWTH RATING 1..100 | 89 | 58 | |
SEASONALITY SCORE 1..100 | 44 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (95). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.
ABBV's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (69). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as BMY (22). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
ABBV's Price Growth Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (45). This means that ABBV’s stock grew somewhat faster than BMY’s over the last 12 months.
BMY's P/E Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as ABBV (89). This means that BMY’s stock grew similarly to ABBV’s over the last 12 months.
| ABBV | BMY | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 33% | 3 days ago 61% |
| Stochastic ODDS (%) | 3 days ago 48% | 3 days ago 47% |
| Momentum ODDS (%) | 3 days ago 68% | 3 days ago 51% |
| MACD ODDS (%) | 3 days ago 74% | 3 days ago 65% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 56% |
| TrendMonth ODDS (%) | 3 days ago 64% | 3 days ago 58% |
| Advances ODDS (%) | 3 days ago 61% | 3 days ago 56% |
| Declines ODDS (%) | 5 days ago 46% | 5 days ago 54% |
| BollingerBands ODDS (%) | 3 days ago 43% | 3 days ago 55% |
| Aroon ODDS (%) | 3 days ago 61% | 3 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while BMY’s FA Score has 1 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- BMY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while BMY’s TA Score has 5 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 4 bearish.
- BMY’s TA Score: 5 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +3.24% price change this week, while BMY (@Pharmaceuticals: Major) price change was +1.63% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.16%. For the same industry, the average monthly price growth was -2.39%, and the average quarterly price growth was +4.91%.
Reported Earning Dates
ABBV is expected to report earnings on Feb 03, 2027.
BMY is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+0.16% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with JNJ. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then JNJ could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +1.41% | ||
| JNJ - ABBV | 51% Loosely correlated | -0.73% | ||
| NVS - ABBV | 49% Loosely correlated | -0.19% | ||
| AMGN - ABBV | 48% Loosely correlated | +1.15% | ||
| BMY - ABBV | 47% Loosely correlated | +1.78% | ||
| MRK - ABBV | 42% Loosely correlated | +2.18% | ||
More | ||||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.